Patents by Inventor Joe Anh Tran

Joe Anh Tran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210139514
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Application
    Filed: April 5, 2019
    Publication date: May 13, 2021
    Inventors: Alexander Russell ABELA, Jeremy J. CLEMENS, Peter Diederik Jan GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Haripada KHATUYA, Jason McCARTNEY, Mark Thomas MILLER, Fabrice Jean Denis PIERRE, Joe Anh TRAN, Jinglan ZHOU
  • Publication number: 20210032272
    Abstract: This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis by administering such modulators and pharmaceutical compositions, and processes for making such modulators.
    Type: Application
    Filed: April 12, 2019
    Publication date: February 4, 2021
    Inventors: Alexander Russell ABELA, Jeremy J. CLEMENS, Peter Diederik Jan GROOTENHUIS, Sara Sabina HADIDA RUAH, Yoshihiro ISHIHARA, Haripada KHATUYA, Jason McCARTNEY, Mark Thomas MILLER, Fabrice Jean Denis PIERRE, Joe Anh TRAN, Jinglan ZHOU
  • Publication number: 20040192676
    Abstract: Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders.
    Type: Application
    Filed: December 19, 2003
    Publication date: September 30, 2004
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: Chen Chen, Fabio C. Tucci, Joe Anh Tran, Caroline Chen, Nicole White
  • Publication number: 20040053933
    Abstract: Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders.
    Type: Application
    Filed: May 9, 2003
    Publication date: March 18, 2004
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: Joseph Pontillo, Dragan Marinkovic, Marion C. Lanier, Joe Anh Tran, Melissa Arellano, Jessica Parker, Jodie Nelson, Chen Chen, Fabio C. Tucci, Caroline Chen, Wanlong Jiang, Nicole White
  • Patent number: 6682938
    Abstract: An analyte sensing fluorescent molecule that employs intramolecular electron transfer is designed to exhibit selected fluorescent properties in the presence of analytes such as saccharides. The selected fluorescent properties include excitation wavelength, emission wavelength, fluorescence lifetime, quantum yield, photostability, solubility, and temperature or pH sensitivity. The compound comprises an aryl or a substituted phenyl boronic acid that acts as a substrate recognition component, a fluorescence switch component, and a fluorophore. The fluorophore and switch component are selected such that the value of the free energy for electron transfer is less than about 3.0 kcal mol−1. Fluorescent compounds are described that are excited at wavelengths greater than 400 nm and emit at wavelengths greater than 450 nm, which is advantageous for optical transmission through skin.
    Type: Grant
    Filed: September 15, 2000
    Date of Patent: January 27, 2004
    Assignees: The Regents of the University of California, Minimed Inc.
    Inventors: Joe H. Satcher, Jr., Stephen M. Lane, Christopher B. Darrow, Douglas R. Cary, Joe Anh Tran
  • Patent number: 6673625
    Abstract: The present invention provides formulae for fluorescent compounds that have a number of properties which make them uniquely suited for use in sensors of analytes such as saccharides. The advantageous fluorescent properties include favorable excitation wavelengths, emission wavelengths, fluorescence lifetimes, and photostability. Additional advantageous properties include enhanced aqueous solubility, as well as temperature and pH sensitivity. The compound comprises an aryl or a substituted phenyl botonic acid that acts as a substrate recognition component, a fluorescence switch component, and a fluorophore. Fluorescent compounds are described that are excited at wavelengths greater than 400 nm and emit at wavelengths greater than 450 nm, which is advantageous for optical transmission through skin. The fluorophore is typically selected from transition metal-ligand complexes and thiazine, oxazine, oxazone, or oxazine-one as well as anthracene compounds.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: January 6, 2004
    Assignees: The Regents of the University of California, MiniMed Inc.
    Inventors: Joe H. Satcher, Jr., Stephen M. Lane, Christopher B. Darrow, Douglas R. Cary, Joe Anh Tran
  • Publication number: 20030158209
    Abstract: Compounds which function as melanocortin receptor ligands and having utility in the treatment of melanocortin receptor-based disorders.
    Type: Application
    Filed: October 9, 2002
    Publication date: August 21, 2003
    Applicant: Neurocrine Biosciences Inc.
    Inventors: Brian P. Dyck, Val Goodfellow, Teresa Phillips, Jessica Parker, Xiaohu Zhang, Chen Chen, Joe Anh Tran, Joseph Pontillo, Fabio C. Tucci
  • Publication number: 20020010279
    Abstract: The present invention provides formulae for fluorescent compounds that have a number of properties which make them uniquely suited for use in sensors of analytes such as saccharides. The advantageous fluorescent properties include favorable excitation wavelengths, emission wavelengths, fluorescence lifetimes, and photostability. Additional advantageous properties include enhanced aqueous solubility, as well as temperature and pH sensitivity. The compound comprises an aryl or a substituted phenyl botonic acid that acts as a substrate recognition component, a fluorescence switch component, and a fluorophore. Fluorescent compounds are described that are excited at wavelengths greater than 400 nm and emit at wavelengths greater than 450 nm, which is advantageous for optical transmission through skin. The fluorophore is typically selected from transition metal-ligand complexes and thiazine, oxazine, oxazone, or oxazine-one as well as anthracene compounds.
    Type: Application
    Filed: March 30, 2001
    Publication date: January 24, 2002
    Inventors: Joe H. Satcher, Stephen M. Lane, Christopher B. Darrow, Douglas R. Cary, Joe Anh Tran